A Landscape Analysis of HIV Cure-Related Clinical Research in 2019

Thumbnail Image

Files

1-s2.0-S205566402031459X-main.pdf (1.09 MB)

Links to Files

https://www.sciencedirect.com/science/article/pii/S205566402031459X

Permanent Link

https://doi.org/10.1016/j.jve.2020.100010
 http://hdl.handle.net/11603/19740

Collections

UMBC Gender & Women's Studies
UMBC Faculty Collection

Author/Creator

Author/Creator ORCID

Date

2020-09-02

Type of Work

journal article postprints
Text

Department

Program

Citation of Original Publication

Liz Barr and Richard Jefferys, A landscape analysis of HIV cure-related clinical research in 2019, Journal of Virus Eradication Volume 6, Issue 4, 100010 (2020), doi; https://doi.org/10.1016/j.jve.2020.100010

Rights

This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Attribution-NonCommercial-NoDerivatives 4.0 International

Subjects

Abstract

Objectives In 2018, we surveyed investigators conducting HIV cure-related clinical research, drawing on information from the online listing established by Treatment Action Group (TAG). The purpose of the survey was to facilitate a landscape analysis of the field. In 2019, we fielded a second survey in order to provide updated information and assess any shifts in the landscape. Methods Trials and observational studies listed as of August 16, 2019 formed the sample set. Survey questions addressed funding, trial development, recruitment, enrollment, participant demographics, antiretroviral therapy status, HIV reservoir assays, invasive procedures, study completion, data sharing and dissemination plans. A survey was sent to the contact(s) for each study. Supplemental information was collected from clinicaltrials.gov and available presentations/publications of study results. Results A total of 97 interventional trials and 36 observational studies were identified, with 30 including analytical treatment interruptions. Total projected enrollment is 13,732 participants, with observational studies contributing the majority (8,325). Most interventional trials are in early phases. The majority of current research is located in the USA, involves predominately male participants and is limited in racial and ethnic diversity. Prespecified demographic enrollment targets are rare. Two thirds of respondents to our previous survey reported that enrollment is progressing more slowly than anticipated. Conclusions A diverse range of interventions are being evaluated in HIV cure research, but participant diversity is far from optimal with a continuing underrepresentation of women. Broadening inclusion and geographic reach will be necessary to achieve the goal of developing widely effective, safe and accessible curative interventions.